Compare UBFO & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UBFO | CGEN |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.7M | 188.2M |
| IPO Year | 2001 | 2001 |
| Metric | UBFO | CGEN |
|---|---|---|
| Price | $10.46 | $2.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 48.2K | ★ 328.1K |
| Earning Date | 04-17-2026 | 05-18-2026 |
| Dividend Yield | ★ 4.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $2,954,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.09 |
| P/E Ratio | $15.01 | ★ N/A |
| Revenue Growth | ★ 1.23 | N/A |
| 52 Week Low | $7.80 | $1.23 |
| 52 Week High | $11.52 | $2.94 |
| Indicator | UBFO | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 79.89 |
| Support Level | $9.31 | $1.45 |
| Resistance Level | $10.53 | N/A |
| Average True Range (ATR) | 0.20 | 0.16 |
| MACD | 0.04 | 0.07 |
| Stochastic Oscillator | 75.00 | 95.83 |
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.